Anpirtoline
| Clinical data | |
|---|---|
| Other names | D-16949; 6-Chloro-2-[piperidinyl-4-thio]pyridine |
| Drug class | Serotonin receptor modulator Serotonin 5-HT1B receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H13ClN2S |
| Molar mass | 228.74 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Anpirtoline (INN; developmental code name D-16949), also known as 2-chloro-6-piperidin-4-ylsulfanylpyridine, is a serotonin receptor modulator which was under development for the treatment of major depressive disorder (MDD) and pain but was never marketed.
It is a serotonin 5-HT1B and 5-HT1D receptor agonist, a serotonin 5-HT1A receptor ligand, a serotonin 5-HT3 receptor antagonist, and also binds to the serotonin 5-HT2 receptors with weak affinity. However, it acts preferentially as a serotonin 5-HT1B receptor agonist and is sometimes described as being selective in this action. It causes a decrease in serotonin synthesis and a reduction in aggressive behavior.
Anpirtoline is a synthetic compound. Anpirtoline hydrochloride appears as a white solid and is soluble in water. Being synthetic, the compound can be purchased from suppliers.